ERBB2 and breast carcinoma: Besides, it is reported that knocking out FOXM1 in breast cancer cells can restore sensitivity to endocrine therapy (Bergamaschi et al., 2014) and FOXM1 plays a role in the development of HER2-targeted therapy resistance (Lam et al., 2009).